Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · IEX Real-Time Price · USD
58.74
+0.50 (0.86%)
At close: Jul 19, 2024, 4:00 PM
59.00
+0.26 (0.44%)
Pre-market: Jul 22, 2024, 7:28 AM EDT
Legend Biotech Employees
Legend Biotech had 1,826 employees as of December 31, 2023. The number of employees increased by 436 or 31.37% compared to the previous year.
Employees
1,826
Change (1Y)
436
Growth (1Y)
31.37%
Revenue / Employee
$187,732
Profits / Employee
-$255,173
Market Cap
10.71B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,826 | 436 | 31.37% |
Dec 31, 2022 | 1,390 | 319 | 29.79% |
Dec 31, 2021 | 1,071 | 189 | 21.43% |
Dec 31, 2020 | 882 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Walgreens Boots Alliance | 331,000 |
Fresenius Medical Care AG & Co. KGaA | 119,845 |
Universal Health Services | 96,700 |
DaVita | 70,000 |
Charles River Laboratories International | 21,800 |
Catalent | 17,800 |
Teleflex | 14,500 |
AptarGroup | 13,800 |
LEGN News
- 12 days ago - Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results - GlobeNewsWire
- 4 weeks ago - Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst - Benzinga
- 6 weeks ago - Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA - Business Wire
- 7 weeks ago - Legend Biotech to Participate in the Jefferies Global Healthcare Conference - Business Wire
- 2 months ago - Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA - Business Wire
- 2 months ago - Legend Biotech Reports First Quarter 2024 Results and Recent Highlights - Business Wire
- 3 months ago - CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma - Business Wire
- 3 months ago - Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results - Business Wire